Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization.

Analysis by response to bridging showed that the patients who achieved CR or PR to bridging therapy showed improved median PFS compared with those who had SD or PD, but this did not reach statistical significance, which was likely due to the small numbers (19.5 months [95% CI: 3.0–NR] vs. 3.1 months [95% CI: 1.0–15.0]; HR 1.89 [95% CI: 0.92–3.89]; P = 0.08; Figure 5A ).

also in 111,027 other papers